Recursion Reports No New Safety Signals in Phase 2 REC-4881
The company reported 81% Grade 1/2 treatment-related adverse events (TRAEs), 15% Grade 3 TRAEs and no Grade 4/5 TRAEs.
The company reported 81% Grade 1/2 treatment-related adverse events (TRAEs), 15% Grade 3 TRAEs and no Grade 4/5 TRAEs.